IMPLEMENTING PRO-COMPETITIVE CRITERIA FOR THE EXAMINATION OF PHARMACEUTICAL PATENTS

Carlos M. Correa
IMPLEMENTING PRO-COMPETITIVE CRITERIA FOR THE EXAMINATION OF PHARMACEUTICAL PATENTS

Carlos M. Correa

SOUTH CENTRE

FEBRUARY 2016
THE SOUTH CENTRE

In August 1995 the South Centre was established as a permanent intergovernmental organization of developing countries. In pursuing its objectives of promoting South solidarity, South-South cooperation, and coordinated participation by developing countries in international forums, the South Centre has full intellectual independence. It prepares, publishes and distributes information, strategic analyses and recommendations on international economic, social and political matters of concern to the South.

The South Centre enjoys support and cooperation from the governments of the countries of the South and is in regular working contact with the Non-Aligned Movement and the Group of 77 and China. The Centre’s studies and position papers are prepared by drawing on the technical and intellectual capacities existing within South governments and institutions and among individuals of the South. Through working group sessions and wide consultations, which involve experts from different parts of the South, and sometimes from the North, common problems of the South are studied and experience and knowledge are shared.
NOTE

Readers are encouraged to quote or reproduce the contents of this Research Paper for their own use, but are requested to grant due acknowledgement to the South Centre and to send a copy of the publication in which such quote or reproduction appears to the South Centre.

The views expressed in this paper are the personal views of the author and do not necessarily represent the views of the South Centre or its Member States. It contains a revised version of a paper prepared for the UNDP Regional Consultation ‘Integrating Public Health Considerations in Pharmaceutical Patenting in LMICs’, 6-7 May 2015, Bangkok, Thailand. Any mistake or omission in this study is the sole responsibility of the author.

South Centre
Ch. du Champ d’Anier 17
POB 228, 1211 Geneva 19
Switzerland
Tel. (41) 022 791 80 50
Fax (41) 022 798 85 31
south@southcentre.int
www.southcentre.int
# Table of Contents

ACRONYMS .................................................................................................................. vii

I.  INTRODUCTION ...................................................................................................... 1

II.  GENERAL RULES REGARDING PATENTABILITY .................................................. 2
    1. The Concept of Invention ..................................................................................... 2
    2. Patentability Standards ...................................................................................... 3
        Novelty .................................................................................................................. 3
        Inventive Step ...................................................................................................... 4
        Industrial Applicability/Utility ............................................................................ 7
    3. Sufficiency of Disclosure ..................................................................................... 7
    4. Flexibilities Under the TRIPS Agreement ........................................................ 8

III. TYPICAL CLAIMS RELATING TO PHARMACEUTICALS ...................................... 10
    1. Markush Claims ................................................................................................. 10
    2. Selection Patents ............................................................................................... 13
    3. Polymorphs ....................................................................................................... 14
    4. Enantiomers ...................................................................................................... 16
    5. Salts ................................................................................................................... 18
    6. Ethers and Esters .............................................................................................. 21
    7. Compositions ..................................................................................................... 21
    8. Doses .................................................................................................................. 22
    9. Combinations .................................................................................................... 23
    10. Prodrugs ........................................................................................................... 24
    11. Metabolites ..................................................................................................... 25
    12. New Medical Use ............................................................................................. 25

IV.  CONCLUSIONS ..................................................................................................... 27
**ACRONYMS**

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPO</td>
<td>European Patent Office</td>
</tr>
<tr>
<td>IR</td>
<td>Infrared Absorption Spectrum</td>
</tr>
<tr>
<td>NMR</td>
<td>Nuclear Magnetic Resonance</td>
</tr>
<tr>
<td>R&amp;D</td>
<td>Research and Development</td>
</tr>
<tr>
<td>TRIPS</td>
<td>The Agreement on Trade-related Aspects of Intellectual Property Rights</td>
</tr>
<tr>
<td>USPTO</td>
<td>US Patent and Trademark Office</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
<tr>
<td>WTO</td>
<td>World Trade Organization</td>
</tr>
</tbody>
</table>
I. INTRODUCTION

This document discusses criteria for implementing the patentability requirements in relation to patent applications covering products and processes, as well as the use of pharmaceutical products. The adoption of rigorous criteria with this purpose is important for four main reasons.

First, although pharmaceuticals share common features with other inventions, there are elements in patent claims relating to pharmaceuticals that are unique, determined by their intended use.

Second, a set of examination criteria will help speed up patent procedures, increase uniformity in the treatment of applications, and offer applicants greater certainty about the possible outcome of the procedures.

Third, there is a proliferation of patent applications in the field of pharmaceuticals claiming polymorphs, salts, formulations and so on, which are often made to prevent generic competition rather than to protect genuine inventions. So-called ‘evergreening’ patents do not contribute to the technological pool, and they limit the market entry of generic products.

Fourth, given the impact of patents on the availability, accessibility and affordability of treatments and technologies, the manner in which pharmaceutical patent applications are examined can have critical implications for public health. Patent offices and examiners play vital roles in ensuring an appropriate balance between protecting inventions and incentivizing innovation on the one hand, and promoting accessibility and affordability of treatments and health technologies on the other. This balancing process is also important for achieving broader development priorities, from national efforts to promote research and development (R&D), technology transfer and pharmaceutical production, to achieving universal health coverage.

Several countries (e.g., Argentina, Ecuador, India and the Philippines) have adopted legislation or policies for examining patent applications relating to pharmaceutical products and processes in a manner that accounts for public health considerations. Analysis of pharmaceutical patent claims has shown that the proper application of patentability standards can prevent the grant of ‘poor quality’ or trivial patents, which, by preventing the timely entry of generic competition, may harm public health.

Importantly, the application of the discussed criteria would not mean to modify the standards of patentability established by patent law, or to add additional standards. Instead, they aim to ensure the correct application of those standards in view of the specific nature of the claimed subject matter and the public health relevance of the decisions.

1 The TRIPS (Trade-related Aspects of Intellectual Property Rights) Agreement does not oblige World Trade Organization members to grant patents claiming a particular use of a product; many countries do not grant patents for the second and subsequent uses of medicines (see below).

2 ‘Evergreening’ is a strategy by which pharmaceutical companies apply for patents over derivatives, formulations, dosage forms, etc. of known drugs in order to extend their exclusive rights beyond the expiry of the original patent.
II. **GENERAL RULES REGARDING PATENTABILITY**

1. **The Concept of Invention**

Most patent laws do not define ‘invention’, leaving the specific boundaries of this concept to patent offices and courts to determine. Generally, an invention may be understood as a technical development **conceived** by an inventor. This notion excludes something that has merely been discovered or otherwise found by chance or as a result of research. For example, a natural gene for which a function has been identified is a discovery, not an invention. In fact, many patent laws specifically exclude discoveries.

The identification of particular properties or physical forms of a known product also does not amount to an invention, despite the efforts entailed in identifying such properties or forms.

India’s *Revised Draft Guidelines for Examination of Patent Applications in the Field of Pharmaceuticals* specifies that: “it should be borne in mind that finding the new property of an already known substance does not make the substance novel and/or inventive.”

As discussed below, identifying the most suitable polymorph for a pharmaceutical product may not be deemed an invention either: a polymorph is an inherent characteristic of a compound in its solid form that is found, not invented. Similarly, finding a new use for a known medicine is not an invention.

The concept of invention may be seen as encompassing a **technical effect**, as is the case under European law. Although the European Patent Convention does not spell out this requirement, the technical character of an invention is generally considered an essential requirement for its patentability. The European Patent Office (EPO), for instance, held in decision T 154/04 (OJ 2008, 46) that ‘technical character’ was an implicit requisite of an ‘invention’ within the meaning of article 52(1) of the European Patent Convention.

---

3 Definitions of ‘invention’ are found in Indonesian Law No. 14 Year 2001 regarding patents (Article 1: invention is “an Inventor's idea that is poured in any activity of solving a specific problem in the field of technology, either in the form of a product or process, or an improvement and development of a product or a process”), and in the Mexican Industrial Property Law of June 25, 1991 (Article 15: “Any human creation that allows matter or energy existing in nature to be transformed for use by man for the satisfaction of his specific needs shall be considered an invention”).

4 The US Department of Justice argued in an *amicus curiae* submitted in a case relating to the patentability of claims over DNA that “the chemical structure of native human genes is a product of nature, and it is no less a product of nature when that structure is ‘isolated’ from its natural environment than are cotton fibers that have been separated from cotton seeds or coal that has been extracted from the earth.” (Available at www.pubpat.org/assets/files/brcA/CAFC/United%20States%20Amicus%20Brief.pdf).

5 See, e.g., article 52(2) of the European Patent Convention.


2. Patentability Standards

Novelty

Generally, universal (or absolute) novelty is required for a valid patent. The concept of novelty, however, may be applied in different ways, depending on the legislation and interpretation by patent offices and courts. In particular, there is room for national policies to determine the scope of what has been disclosed and is therefore part of the ‘prior art’.

The disclosure of an invention in the prior art may not have been made expressis verbis, but may be implicit in a prior art document. Implicit teachings can be considered part of the prior art, hence destroying the novelty of an invention. This approach is preferable to the ‘photographic’ approach to novelty, which is based on explicitly disclosed information. The photographic approach entails a rigid and formalistic assessment of novelty, which may lead to the unwarranted grant of patent rights. The EPO’s jurisprudence has clearly relied on the implicit features to establish novelty. In T 0701/09, for instance, the EPO Board found that:

direct and unambiguous disclosure was not limited to explicit or literal statements, but equally included implicitly disclosed information which a reader skilled in the art would unequivocally gather from the overall context of a cited document.\(^8\)

In accordance with the guidelines applied by the US Patent and Trademark Office (USPTO): “the express, implicit, and inherent disclosures of a prior art reference may be relied upon in the rejection of claims under 35 U.S.C. 102 or 103.”\(^9\)

The Indian Revised Draft Guidelines for Examination of Patent Applications in the Field of Pharmaceuticals note in this regard:

Implicit disclosure: The lack of novelty must normally be clearly apparent from the explicit teaching of the prior art. However, if the said prior art discloses the claimed subject-matter in such implicit manner that it leaves no doubt in the mind of examiner as to the content of the prior art and the practical effect of its teaching, an objection regarding lack of novelty should be raised.\(^10\)

Novelty may also be excluded when the information available in the prior art discloses the essential elements of an invention, regardless of whether data enabling the execution of the invention were available. Thus, novelty will be destroyed if a compound was made and tested, even if a clear description of its properties or a method of making it was not disclosed.

In Enercon (India) Limited v. Aloys Wobben ORA/6/2009/PT/CH.ORDER (No. 18 of 2013) the Intellectual Property Appellate Board of India noted that novelty may be denied on the basis of ‘inherent anticipation’. It stated:

---

\(^10\) Revised Draft Guidelines for Examination of Patent Applications in the Field of Pharmaceuticals, para. 7.4.
the prior art reference may anticipate without disclosing a feature of the claimed invention if that missing characteristic is necessarily present, or inherent, in the single anticipating prior art... it is not necessary that inherent anticipation requires that a person of ordinary skill in the art at the time would have recognized the inherent disclosure. But it is necessary that the result is a necessary consequence of what was deliberately intended in the invention.

In accordance with US case law:

the discovery of a previously unappreciated property of a prior art composition, or of a scientific explanation for the prior art’s functioning, does not render the old composition patentably new to the discoverer.” *Atlas Powder Co. v. Ireco Inc.*, 190 F.3d 1342, 1347, 51 USPQ2d 1943, 1947 (Fed. Cir. 1999). Thus the claiming of a new use, new function or unknown property which is inherently present in the prior art does not necessarily make the claim patentable (*In re Best*, 562 F.2d 1252, 1254, 195 USPQ 430, 433 (CCPA 1977).  

The number of documents that examiners may consider in determining whether novelty has been destroyed is an important question. Although general practice has been to consider a single document, patent law does not rule out the possibility of considering more than one document.

Many laws specify that the prior art should be deemed to include applications filed in the same country that are published on or after the filing date of the application being examined.

**Inventive Step**

The patent system was devised to reward inventiveness, encourage technical progress and foster the dissemination of innovations. Restricting the free movement of ideas, as the granting of a patent entails, is only justified when the applicant has devised a new product or process as an outcome of an ‘inventive activity’ or ‘inventive step’.

Generally, patent laws define inventive step (or non-obviousness) based on a legal fiction. They assume a judgment made by a person skilled in the art, with ordinary knowledge or expertise in a given technical field. The determination of the knowledge and capability of such a person is crucial to ensuring that the patent system rewards those who contribute new technical solutions, and to avoiding the grant of patents over minor or trivial developments that may block innovation or exclude legitimate competition. This is particularly important in the pharmaceutical sector, where patents are often strategically used to deter the market entry of generic medicines at lower prices.

---

13 See, e.g., article 3(3) of Indonesian patent law No. 14, 2001.
A patent system that rewards innovation should be based on an analysis of what is evident or obvious for an expert, or a team of experts. In many cases, an invention requires technical contributions from specialists from different fields. Hence, considering the expert knowledge of one person would be insufficient. In a case relating to European patent EP 0 347 066 on two enantiomers of the antidepressant drug citalopram, for instance, the Tribunal de Grande Instance of Paris (30-09-10) ruled that the ‘skilled person’ must be defined as a team composed of a medicinal chemist, a pharmacologist and a biochemist working in the pharmaceutical industry.\footnote{Société Ratiopharm GmbH v. Société H. Lundbeck AIS, available at http://kluwerpatentblog.com/files/2011/02/2010-09-30_TGI_Paris_Ratiopharm_vs_Lundbeck.pdf.}

Examiners should consider not only what is formally documented in the prior art, but also what an expert, such as a person trained and experienced in disciplines relevant to the pharmaceutical sector, could consider evident in the light of such prior art. Thus, the identification of a pharmaceutically suitable salt to manufacture a medicine, or its formulation to ensure a certain release characteristic (e.g. slow release) of the active ingredient, are part of the common knowledge of people working in those fields. Only in very rare occasions will a salt or formulation, even if new, comply with a rigorously applied inventive-step requirement. In relation to US patent number 4,879,303 on the besylate of amlodipine salt, for instance, the US Court of Appeals for the Federal Circuit stated that:

\begin{quote}
a suggestion, teaching, or motivation to combine the relevant prior art teachings to achieve the claimed invention does not have to be found explicitly in the prior art references sought to be combined, but rather “may be found in any number of sources, including common knowledge, the prior art as a whole, or the nature of the problem itself.\footnote{Pfizer, Inc. v. Apotex, Inc., 2006-1261; 22 March 2007.}
\end{quote}

In accordance with the EPO Guidelines for Examination,

Common general knowledge can come from various sources and does not necessarily depend on the publication of a specific document on a specific date. An assertion that something is common general knowledge need only be backed by documentary evidence (for example, a textbook) if this is contested.\footnote{Available at www.epo.org/law-practice/legal-texts/html/guidelines/e/g_vii_3_1.htm.}

Although some patent laws refer to a person with an ‘average’ or ‘ordinary’ knowledge,\footnote{For instance, in the United States, non-obviousness is judged in the light of the knowledge of a ‘person having ordinary skill in the art’ (35 U.S.C. § 103 (A)).} this does not mean that he/she has no creativity. In \textit{KSR v. Teleflex}, for instance, the US Supreme Court held that “a person of ordinary skill is also a person of ordinary creativity, not an automaton.”\footnote{See \textit{KSR Int'l Co. v. Teleflex}, Inc., 550 U.S. 398 (2007).}

This means that the person skilled in the art should be deemed to be a person who can derive new knowledge from the prior art, even with experimentation when it does not entail methods unknown to an expert in the field. In accordance with the Indian \textit{Revised Draft Guidelines for Examination of Patent Applications in the Field of Pharmaceuticals}:
[t]his hypothetical person [the person skilled in the art] is presumed to know all the prior arts as on that date, even non-patent prior art available to public. He has knowledge of the technical advancement as on that date, and the skill to perform experiments with the knowledge of state of the art. He is not a dullard and has certain modicum of creativity.\textsuperscript{19}

In many cases, the examiner will have to consider whether it was obvious for a person skilled in the art to carry out certain activities, for instance, to obtain a salt or a polymorph of a compound of medical use. The ‘obvious to try’ test, as applied in some jurisdictions, requires consideration of the reasonable expectation of success, even when experimentation is required. For instance, the Indian \textit{Revised Draft Guidelines for Examination of Patent Applications in the Field of Pharmaceuticals}, provide that:

the reasonable expectation of success embedded in the prior art which motivates the skilled person to reach to the invention, is the most crucial determining factor in ascertaining inventive step. Obviousness cannot be avoided simply by showing of some degree of unpredictability in the art so long as there was a reasonable probability of success. Obviousness does not require absolute predictability of success. All that is required is a reasonable expectation of success. In the matter of pharmaceutical inventions structural and functional similarity of the product provides this motivation to combine the teachings of the prior arts. A surprising effect, synergistic outcome of the combinations, prior art prejudice etc. usually demonstrates the non-obvious nature of the invention.\textsuperscript{20}

In countries that apply what is known as the ‘problem-solution’ approach\textsuperscript{21} to determining inventive step, finding a solution to a problem is not sufficient to establish a patentable invention. The solution must be, in itself, the outcome of an inventive activity. In particular, a claim that the proposed solution offers certain advantages (for instance, increased bio-availability of a medicine) is not enough to establish an inventive step.

In some cases, the surprising or unexpected nature of the results obtainable with a new product may be an indicator of inventive step. However, this is not necessarily the case. The EPO Board of Appeals, for instance, decided that:

if, having regard to the state of the art, it would already have been obvious for a skilled person to arrive at something falling within the terms of a claim, because an advantageous effect could be expected to result from the combination of the teachings of the prior art documents, such claim lacked inventive step, irrespective of the circumstance that an extra effect (possibly unforeseen) was obtained (T 21/81).\textsuperscript{22}

Where, because of an essential part of the technical problem being addressed, the state of the art obliged a skilled person to adopt a certain solution, that solution was not automatically rendered inventive by the fact that it also unexpectedly solved part of

\textsuperscript{19} Revised Draft Guidelines for Examination of Patent Applications in the Field of Pharmaceuticals, para. 18.
\textsuperscript{20} Ibid., para. 8.8.
\textsuperscript{21} This methodology was developed by the EPO pursuant to the European Patent Convention Rule 27(1)(c). It is applied by many countries whose practice has been influenced by the technical assistance and training offered by the EPO.
\textsuperscript{22} Available at \url{www.epo.org/law-practice/legal-texts/html/caselaw/2013/e/cfr_i_d_10_8.htm}. 
the problem. Therefore, an unexpected bonus effect does not confer inventiveness on an obvious solution (T 231/97).\footnote{Ibid.}

While some patent offices have limited the number of documents that may be considered in assessing inventive step, there is no rationale for such limitations. The assessment should include the prior art as a whole.

**Industrial Applicability/Utility**

While some countries, such as the United States, only require that the utility of a claimed invention be shown in the patent application, most countries apply an industrial applicability standard. An industrial applicability standard imposes a higher burden on the applicant than the utility standard, and it excludes the patentability of certain types of claims common in the pharmaceutical sector. Industrial applicability means that a product can be manufactured or a technical process applied in accordance with the teachings disclosed in a patent. Thus, a patent application describing a process that may be applied only in a laboratory, or how to use a medicine to achieve a certain therapeutic effect, would not be patentable.

Industrial applicability means that an invention can be made in industry.\footnote{‘Industry’ is broadly understood in accordance with article 1(3) of the Paris Convention for the Protection of Industrial Property, including what is applicable “to industry and commerce proper, but likewise to agricultural and extractive industries and to all manufactured or natural products, for example, wines, grain, tobacco leaf, fruit, cattle, minerals, mineral waters, beer, flowers, and flour.”} An industrial applicability requirement rules out the patentability of inventions whose effects take place as the result of physiological or pharmacological actions that take place in the body. For instance, a new therapeutic use or changes in dosages of a known medicine would not be patentable.

Complex issues arise in determining the industrial applicability or utility of claims relating to new and as yet unproven drugs. Pharmaceutical companies generally file patent applications before completing clinical studies. Hence, the efficacy and safety of the drug has not been determined. Patent offices and courts generally accept this fact, but request that some evidence be provided to support an application. In the United States, for instance, the examiner is not expected to seek evidence on safety or efficacy of treatments for humans to demonstrate utility, but will examine the nature of disease in relation to the asserted utility. In the case of diseases known to be incurable at the time of filing, the examiner will review the asserted utility with this in mind. Claims for curing or preventing a disease generally require greater proof of utility compared to claims for method of treatment or treating a symptom; in the latter case, adequate test data can be a sufficient evidence for utility.\footnote{Carlos Correa (editor), *A Guide to Pharmaceutical Patents*, South Centre, 2012, p. 103.}

3. **Sufficiency of Disclosure**

In addition to complying with patentability requirements, the grant of a patent is generally conditional upon the sufficient disclosure of the invention. In other words, the specifications should provide information to allow a person skilled in the art to make or practice the claimed invention. In accordance with Article 83 of the European Patent Convention, for instance, an application must “disclose the invention in a manner sufficiently clear and complete for it to
be carried out by a person skilled in the art.” This requirement aims at ensuring that an “actual technical contribution to the art” is made; it justifies the grant of a patent monopoly.  

In the United States, the patent specification should allow a “person of ordinary skill in the art” to make and use the invention without “undue experimentation.”

Lack of sufficient disclosure is often a reason for the refusal of a patent application or the revocation of a patent. This is a matter of substance, not form. The ‘Markush claims’ discussed below, for instance, raised an issue of insufficient disclosure: only a few examples of realization for a great number of compounds are disclosed. The same objection may be raised when a patent application generically claims formulations, salts, polymorphs, and so on, without characterizing them, as discussed below.

The knowledge attributed to a person skilled in the art for assessing sufficiency of disclosure needs not be the same as the knowledge attributed for assessing inventive step. To ensure a description of the invention that is understandable to a person with average knowledge, “the skilled person, in the context of sufficiency of disclosure should be a person who without undue burden of experimentation would be able to translate the specification into the technical reality.”

4. Flexibilities Under the TRIPS Agreement

The Agreement on Trade-related Aspects of Intellectual Property Rights (TRIPS Agreement) establishes minimum standards for the protection of intellectual property rights by members of the World Trade Organization (WTO). However, it has left many ‘flexibilities’ that allow members to define their own policies and standards on various matters.

An important flexibility allowed to WTO members is to determine what is meant by ‘invention’, a concept that is not defined in the TRIPS Agreement. In fact, there is significant diversity in national laws and practices around the notion of invention, and to date, no complaint has been raised to the WTO regarding a definition of invention. In particular, national laws may require a determination of whether an invention exists before entering into the analysis of compliance with the patentability requirements.

Similarly, the TRIPS Agreement obligates WTO members to grant a patent when patentability requirements are met, but it does not define those requirements. Thus, WTO members may adopt different concepts of novelty (universal, local, or a mix of them); inventive step or non-obviousness; and industrial applicability or utility. Nothing prevents WTO members from applying rigorous patentability criteria to avoid low-quality patents. Similarly, WTO members retain flexibility to determine the rules applicable to the disclosure

---

26 See, e.g., T 409/91, para. 155-156.
27 35 USC 112: “The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same...”
of the invention, in order to ensure its reproducibility and avoid broad, generic claims, as is the case with the Markush claims (see discussion below).

The UN High Commissioner for Human Rights has stated that:

[t]he requirements under the TRIPS Agreement for the grant of patents – novelty, inventive step and industrial applicability – are open to interpretation under national legislation and each country can decide according to local conditions. Consequently, the High Commissioner encourages interpretations of these requirements that do not lose sight of the public interest in the wide dissemination of knowledge. 31

The World Health Organization (WHO) Commission on Intellectual Property Rights, Innovation and Public Health also noted that:

[t]he TRIPS agreement allows countries a considerable degree of freedom in how they implement their patent laws, subject to meeting its minimum standards including the criteria for patentability laid down in TRIPS. Since the benefits and costs of patents are unevenly distributed across countries, according to their level of development and scientific and technological capacity, countries may devise their patent systems to seek the best balance, in their own circumstances, between benefits and costs. Thus developing countries may determine in their own ways the definition of an invention, the criteria for judging patentability, the rights conferred on patent owners and what exceptions to patentability are permitted, provided these are consistent with the relevant articles of TRIPS (for WTO Members). 32

The Doha Declaration on the TRIPS Agreement and Public Health confirmed the right of WTO members to use the TRIPS flexibilities. 33

Adopting specific guidelines in relation to the examination of patent applications for pharmaceuticals does not violate the non-discriminatory clause contained in article 27.1 of the TRIPS Agreement. Countries that decide to develop and apply specific guidelines to ensure that patent applications relating to pharmaceuticals are rigorously examined act in conformity with the TRIPS Agreement. The Declaration on Patent Protection: Regulatory Sovereignty under TRIPS developed under the auspices of the Max Planck Institute for Innovation and Competition confirms that:

[e]very technology is more or less unique with regard to its exposure to market failure, its susceptibility to patent protection, and its socio-economic implications. . . Measures to accommodate these differences cannot be considered contrary to Article

33 Paragraph 4: “We agree that the TRIPS Agreement does not and should not prevent members from taking measures to protect public health. Accordingly, while reiterating our commitment to the TRIPS Agreement, we affirm that the Agreement can and should be interpreted and implemented in a manner supportive of WTO members’ right to protect public health and, in particular, to promote access to medicines for all. In this connection, we reaffirm the right of WTO members to use, to the full, the provisions in the TRIPS Agreement, which provide flexibility for this purpose.” Available at www.wto.org/english/thewto_e/minist_e/min01_e/mindec1_trips_e.htm.
27(1) of the TRIPS Agreement. While that provision prohibits discrimination as to the field of technology, it does not prevent states from treating different situations differently. Differentiation that serves to level the actual conditions of competition across all fields of technology is not discriminatory but rather the opposite. It constitutes a necessary response to the diversity of technologies and, consequently, a *conditio sine qua non* for an intrinsically balanced system of protection that remains neutral in its effects on competition. Differentiation may relate to the requirements of patentability, patent eligibility and disclosure,..., to the exclusion of subject matter from patentability, as well as to the scope of protection.  

III. **Typical Claims Relating to Pharmaceuticals**

1. **Markush Claims**

‘Markush claims’\(^\text{35}\) consist of a generic chemical structure with multiple alternatives that allow for the protection, under a single patent, of several variants of a claimed invention. The admission of pharmaceutical patents for such claims raises complex issues because a single patent may potentially block research and development and the commercialization of up to several million molecules.\(^\text{36}\) Recent studies show a growing use of Markush claims in several developing countries, where such claims accounted for more than 50 percent of all patent applications relating to pharmaceuticals.\(^\text{37}\)

Figure 1 presents an example of a generic chemical structure based on a Markush claim.

Figure 1

**A Generic Chemical Structure**

---

\(^{34}\) Available at www.ip.mpg.de/en/pub/news/patentdeclaration.cfm.  
\(^{35}\) Dr. Eugene A. Markush was the founder and president of Pharma Chemical Corporation of Bayonne, New Jersey. He was a leading manufacturer of dyes in the United States and held over 20 patents on synthetic dyes and related fields. In 1924, he obtained a patent on pyrazolone-based dyes (U.S. No. 1,506,316), which protected a generic chemical structure, in addition to the products already synthesized, using the expression ‘where R is a group selected from’. While Dr. Markush did not file the first patent with a generic chemical structure, he was involved in a precedent-setting legal case in the United States for this type of claim.  
\(^{36}\) Eli Lilly’s patent CA 1,075,687 (1975), for instance, covered 15 trillion of compounds “useful in the treatment of mild anxiety states and certain kinds of psychotic conditions such as schizophrenia.”  
The compounds covered by a Markush claim may be determined by a combination of variations that can give rise to a potentially infinite set of alternatives. Variations include:

- substituent variation based on alternative values for an R-group
- position variation depending on the point of attachment
- frequency variation due to multiple occurrence of groups
- homology variation depending on the attached groups (e.g. alkyl, methyl or ethyl)

Typically, patent applications based on Markush claims present a few implementation examples, while the general formula may cover thousands or millions of possible embodiments of the claimed invention. Hence, Markush claims raise issues concerning sufficiency of disclosure: it is impossible to know the peculiarities of the process for obtaining each of the non-exemplified embodiments and whether they will perform the disclosed functions.

Markush claims have become increasingly complex and excessively broad, for instance: “R1 is a substituted or unsubstituted, mono-, di- or polycyclic, aromatic or non-aromatic carbocyclic or heterocyclic ring system, or...” Such claims may disguise the true nature of the invention and cover compounds that lack the activity indicated in the patent application.

In addition, it is virtually impossible to make prior art searches to establish novelty and inventive step for thousands or millions of compounds. Although there are tools that may aide in the examination process, they do not permit a complete and accurate assessment. Several computer-based tools may be required for a comprehensive retrieval, but their use is complex and they do not guarantee accurate results.

Patent offices have adopted or proposed different measures aimed at reducing the scope of Markush-type claims. The Indian Revised Draft Guidelines for Examination of Patent Applications in the Field of Pharmaceuticals, for instance, requires that the complete specification be ‘critically examined’; specific guidance is also provided in the Argentine guidelines (see Box 1).

---

39 For instance, in 2007 the USPTO published proposed new rules, which were not finally enacted, for the "Examination of Patent Applications That Include Claims Containing Alternative Language." Under these rules, nested Markush structures would be banned and an enumeration of alternatives would be required. The proposed rules also required that "the number and presentation of alternatives in the claim does not make the claim difficult to construe." The Supplementary Guidelines for Determining Complaince with 35 U.S.C. 112 and for Treatment of Related Issues in Patent Applications, 76 Fed. Reg. 7,162 (9 February 2011) required a "single structural similarity" for the admissibility of Markush claims and clarified that “[m]embers of a Markush group share a ‘single structural similarity’ when they belong to the same recognized physical or chemical class or to the same art-recognized class.” It also stated that a Markush group share a “when they are disclosed in the specification or known in the art to be functionally equivalent.” See Prior, Kimberly J., "The USPTO’s Historic Struggle with Markush Claims: Will the 2011 Guidelines Provide Relief?" (2012), Student Scholarship, Paper 114. http://erepository.law.shu.edu/student_scholarship/114.
Box 1
Criteria for the Examination of Markush Claims

**India**

While examining Markush claims, the complete specification should be critically examined to determine whether (i) it discloses the best representatives, as known to the applicant, of the possible embodiments; (ii) such embodiments share a common use or property; (iii) such possible embodiments share common structure; (iv) physical and/ or chemical properties of claimed compound are disclosed; (v) test conducted for the representatives of such embodiments is provided...; (vi) in case of product claims, at least one process for preparing the compounds should be disclosed provided that the process enables the whole scope of the invention.

Moreover, if any one of (i) to (vi) are not met, such a Markush claims may be objected depending upon the circumstances of the application so examined under 'Unity of invention' and insufficiency of disclosure suitably.

When the Markush grouping is for alternatives of chemical compounds, the alternatives are regarded as being of a similar nature where the following criteria are fulfilled: (A) all alternatives have a common property or activity; AND (B)(1) a common structure is present, that is, a significant structural element is shared by all of the alternatives; OR (B)(2) in cases where the common structure cannot be the unifying criteria, all alternatives belong to a recognized class of chemical compounds in the art to which the invention pertains.

**Argentina**

Compounds represented by a Markush formula shall be admissible only if unity of invention is demonstrated, if they comply with the requirements for patentability (novelty, inventive step and industrial application) and if the specification sufficiently describes how to obtain all of the compounds provided by the claimed Markush formula.

When an invention involves multiple compounds claimed under a Markush-type formula, a reasonably logical and proportional relationship between the scope of the claims and the related matter disclosed in the description shall be required. The description should include experimental procedures which, taking into account combinations of different substituents or reasonably acceptable equivalents thereof, are representative of the entire scope of the claimed matter. If the working examples are not sufficiently representative of the claimed scope of the invention, and therefore the claims lack sufficient support in the description, the applicant should be required to limit it.

For a sufficient description of the compounds included in the claimed Markush formula, the embodiments of the invention described in the working examples should be representative of all the compounds to be protected. In all cases, these embodiments shall be perfectly exemplified by providing all the data characterizing the compound obtained by physicochemical characterization techniques (such as melting point, boiling point, -IR- infrared spectrum, proton nuclear magnetic resonance -1HNMR- and carbon 13-13CRMN-), indicating whether polymorphic compounds have been detected.
Thus, the protection of Markush formulas should be limited to the matter supported by the description, that can be effectively reproduced by a person skilled in the art and whose industrial application comes up unambiguously from the description.

2. Selection Patents

In some cases, a subgroup of elements is selected from a larger group and claimed on the ground that a new, unexpected property has been found. For instance, if a Markush claim was admitted in relation to a set of pharmaceutical compounds, the patent owner might later file a new patent application covering one or more of such compounds. Thus, the patent owner may obtain a further 20-year monopoly simply by picking one or more compounds out of the generic formula.

Selection patents are also often filed when a starting compound is selected from a list and there is a choice of processes to obtain a final product. In T12/81, for instance, the EPO considered a case where the prior art listed 20 starting compounds and gave a choice among five processes for reducing ketones to their corresponding secondary alcohols, which could take two diastereomeric forms. In other cases, the selection may take place within a numerical range, for instance, when C2 is selected from a previously disclosed compound including a chain range C1-C4. Selection patents are examined in several jurisdictions using different criteria. For instance, in accordance with the EPO Guidelines for Examination, an application would be acceptable (provided that the patentability criteria are met) in the case of the selection of “individual chemical compounds from a known generic formula whereby the compound selected results from the selection of specific substituents from two or more ‘lists’ of substituents given in the known generic formula. The same applies to specific mixtures resulting from the selection of individual components from lists of components making up the prior art mixture.” Under the EPO rules and jurisprudence, the selection within a numerical range is also acceptable if (a) the selected sub-range is narrow compared to the known range; the selected sub-range is sufficiently far removed from any specific examples disclosed in the prior art and from the end points of the known range; and (c) the selected range is not an arbitrary specimen of the prior art, i.e., not a mere embodiment of the prior art, but another invention (purposive selection, new technical teaching). The EPO’s admission of selection patents is based on a fiction of novelty: a prior generic disclosure is considered to not deprive the specific selected item from novelty.

In Germany, the novelty standard has been strictly applied, leading to the rejection of patentability of selections. The disclosure of a group of compounds, even if large, has been deemed to destroy the novelty of each component of the group. In the case of selections within a range, the Federal Supreme Court’s decision in Inkrustierungs-inhibitoren - 2 - of 1999 established that the specification of a range of quantity or weight lacks novelty, as it is a simplified notation of the numerous possible values between the upper-limit value and the lower-limit value. Thus, a selection deemed patentable by the EPO may be regarded as non-eligible in Germany in the light of the same prior art. In the United Kingdom, it has

41 Ibid.
42 Ibid.
traditionally been considered that in order to be patentable, the selection must possess a special advantage judged in the context of the inventive step requirement. In Canada, the unexpected advantages are primarily treated as a matter of utility, under the ‘promise doctrine’ developed by the courts.

The variety of approaches to selection patents illustrates the flexibilities available to patent offices and courts when dealing with this issue. Importantly, WTO members are not obliged to introduce a fiction of novelty in order to consider that a selection of disclosed compounds is still eligible for patent protection based on the rule that a generic claim does not disclose its specific components.

The grant of selection patents, if allowed, implies that the coverage of a patent may be much wider than its disclosure. In order words, while the holder of the patent would get protection on all the embodiments of the basic patent, the subsequently selected elements (although protected) would be considered as not disclosed (and, hence, novel). This argument was rejected by the Supreme Court of India in Novartis AG v. Union of India & Others (Judgment of 1 April 2013). It stated that:

…a monopoly is granted to a private individual in exchange of the invention being made public so that, at the end of the patent term, the invention may belong to the people at large who may be benefited by it. To say that the coverage in a patent might go much beyond the disclosure thus seem to negate the fundamental rule underlying the grant of patents.

3. Polymorphs

Most drugs exhibit structural polymorphism, which appears in the solid state of a chemical compound. Polymorphism is the ability of the chemical molecules or ions to exist with different internal crystal structures.

The techniques to obtain and characterize polymorphs (including hydrates/solvates) are well known to, and normally practiced by, a person skilled in the pharmaceutical field.

---

43 See e.g., Beecham v Bristol (HL) [1978] RPC 521 at 579.
46 Two types of polymorphism are usually distinguished: ‘packing polymorphism’, which results from a difference in crystal packing, and ‘conformational polymorphism’, which results from different conformers of the same molecule.
Such a person will generally seek to obtain the most thermodynamically stable polymorph of the drug to assure a reproducible bioavailability over the drug’s shelf-life, including under a variety of storage conditions. Polymorphs of drug substances are obtained through standard crystallization methods with the intervention of variable thermodynamic and kinetic factors such as temperature, humidity and time.

Polymorphism is an inherent property of a substance; hence, polymorphs are not ‘created’ but found. In some cases, polymorphs can occur unintentionally during production or storage of a drug. One example was Abbott’s molecule inhibitor of HIV protease (ritonavir) marketed as ‘Norvir’. During the manufacture of ritonavir in 1998, unexpectedly, a new unmarked polymorph emerged, interrupting production. In other cases, a polymorph is so unstable that it cannot be obtained in repeated laboratory attempts. As noted in proceedings before a US court, “[b]y the early 2000s, skilled artisans would have appreciated that drug products preferably contain a compound’s most stable polymorph because metastable polymorphs may convert during manufacture or storage.”

A large number of patents have been filed on polymorphs and many were granted. However, patent offices and courts have become increasingly reluctant to grant such patents, and in some countries, they are rejected as a matter of course. In decision T 777/08 of 24 May 2011, the EPO Technical Board of Appeal, for instance, held:

at the priority date of the patent in suit, it belonged to the routine tasks of the skilled person involved in the field of drug development to screen for solid-state forms of a drug substance. For the sake of completeness, the board therefore wishes to note that, in the absence of any technical prejudice, which has not been alleged by the appellant, the mere provision of a crystalline form of a known pharmaceutically active compound cannot be regarded as involving an inventive step. ‘Crystalline products are generally the easiest to isolate, purify, dry and, in a batch process, handle and formulate.’ Thus, in view of his general knowledge, as reflected in this excerpt from document (28), the skilled person, starting from the amorphous form of a pharmaceutically active compound as closest prior art, would have a clear expectation that a crystalline form thereof would provide a solution to the problem as defined [the

49 There are occasional situations in which the development of a meta-stable crystalline or amorphous form is sought, such as to achieve faster dissolution rates or higher concentrations, for instance, for rapid absorption. See e.g., Saifee, Maria; Inamdar, Nazma; Dhamecha, Dinesh L.; Rathi, Amit A, ‘Drug Polymorphism: A Review’. International Journal of Health Research, December 2009, Vol. 2 Issue 4, p. 291.
50 For instance, the US Food and Drug Administration Guideline indicated as early as 1987 that “the manufacturing process (or storage condition)” may produce “particular polymorphs or solvates.” It also noted that “[r]outine storage conditions, as well as some conditions of product manufacture (e.g., tablet compression, or use of an organic solvent during granulation) may also cause [polymorphic] transformations.”
provision of atorvastatin in a form having improved filterability and drying characteristics].

In applying this doctrine, the EPO refused a patent application (EP No. 01924250) covering lopinavir’s crystalline forms on the grounds that there were no unexpected advantages over Abbott Laboratories’ earlier patent for the amorphous form, and that no inventive step was present. It has also been noted that it is increasingly difficult to obtain a patent on a polymorph in the United States, or to defend its validity if challenged in court. In India, the Supreme Court confirmed on 1 April 2013 the refusal of a patent filed by the Swiss pharmaceutical firm Novartis on a crystalline form of an anti-cancer drug (imatinib mesylate). The refusal was based on a finding that increased therapeutic efficacy had not been proven as required by section 3(d) of the Indian Patent Act.

In some cases, patent applications generically refer to polymorphs of a drug without specifically describing them, as in WO0172687 (A1): “Diphenyl ether compounds useful in therapy” published on 4-10-2001, covering a ‘compound of general formula (I), or pharmaceutically acceptable salts, solvates or polymorphs thereof’. Such references do not meet the sufficiency of disclosure requirement established by most patent laws. The same applies to generic references to salts, ethers/esters and prodrugs, as noted below.

Polymorphs cannot be conceived a priori by a person skilled in the art. They are simply found in the solid states of drugs using routine techniques and are characterized by conventional methods based on X-ray diffraction. Accordingly, polymorphs cannot be considered an ‘invention’ as defined above. Even if, however, they were eligible for patent protection, they would not show inventive activity, as it is obvious for a person in the field to seek the most suitable polymorph for achieving properties desirable for pharmaceutical use.

Occasionally, a process to obtain a polymorph may be novel and inventive. However, these standards shall not be considered met simply because it has been difficult to implement such a process; the process should be non-obvious for an expert in the field.

4. Enantiomers

Enantiomers are chiral molecules that are mirror images of one another (see figure 2). They have identical physical characteristics (energy, solubility in typical achiral solvents, boiling and melting points, NMR and IR spectra, etc.) except for their ability to rotate plane-polarized light (optical activity). A ‘racemic mixture’ contains an equal amount of each enantiomer. The techniques applicable to separate enantiomers in a racemic mixture are well known. They include the formation of diastereomeric salts and the use of chiral

---

58 ‘Chiral’ means that the molecules are mirror images of each other and they are not superimposable, i.e., they cannot be placed in the same space in such a way that they will overlap.
chromatography. Reactions can also be used (with chiral reagents or chiral catalysts) that are enantioselective.

Figure 2
Enantiomers

A large proportion of the drugs on the market today are chiral. A person skilled in organic chemistry in the pharmaceutical sector is well aware that the individual enantiomers in a racemic mixture frequently differ in their biological/therapeutic effects, and that the mixture’s pharmacological activity is normally attributable to one of the enantiomers. It is also known\(^{60}\) that the inactive enantiomer may show undesired side or even toxic effects. \(^{61}\) Patent applications often claim an isolated enantiomer and its method of isolation.

There are several grounds for questioning the patentability of individual enantiomers when the racemic mixture is already known.

First, an enantiomer is necessarily present in, or inherent to, a racemic mixture. If the molecular structure of the racemic mixture is known, even in a bi-dimensional form, the presence of a chiral carbon necessarily discloses the existence of both enantiomers. The patentability of an isolated enantiomer may be refused on the grounds of the inherency doctrine, as noted above. In fact, the pharmacological/therapeutic effect of a racemic mixture is almost entirely or entirely based on the active enantiomer. Hence, an individual enantiomer lacks novelty.

Second, for a person skilled in pharmaceutical R&D, it is obvious to identify and isolate the therapeutically active enantiomer. The concept of ‘obvious to try’ is applicable here in assessing inventive step, independent of the availability of prior documents specifically referring to the particular compound.

Third, although the separation of enantiomers in a racemic mixture may be difficult (given that they have the same boiling points, melting points and solubilities), overcoming

---


\(^{61}\) One classic example is thalidomide, synthesized in 1953 by Chemie Grünenthal, a West German company. Thalidomide’s ‘R’ isomer has sedative effects while the ‘S’ enantiomer is teratogenic. It was found that when only one of the optical isomers is administered, both enantiomers are formed in a roughly equal mix in the blood (see, e.g., [www.chm.bris.ac.uk/motm/thalidomide/optical2iso.html](http://www.chm.bris.ac.uk/motm/thalidomide/optical2iso.html)). Although withdrawn from the world market when its teratogenic effect was discovered, thalidomide was later reintroduced for use in various dermatologic conditions thought to have an autoimmune or inflammatory basis. See, e.g., Stephanie Tseng, Grace Pak, Kenneth Washenik, Miriam Keltz Pomeranz, and Jerome L Shupack, ‘Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses’, *JAAD*, volume 35, Issue 6, pp. 969-979.
these difficulties is not equivalent to showing inventive activity. The process for isolation of enantiomers may involve, in some circumstances, an inventive step when the claimed method incorporates unexpected or surprising elements. However, difficulty in isolating and purifying an enantiomer is not per se an indicator of inventive activity.

Litigation relating to enantiomers illustrates that, if correctly applied, the inventive step standard would disallow the protection of enantiomers. For instance, on 29 September 2009, the Full Court of the Federal Court of Australia found that all of the claims in Sanofi-Aventis’ patent number 597784 were invalid for lack of inventive step. This included claims to a single enantiomer, particular clopidogrel salts and a process for preparing the enantiomer.  

5. Salts

Salts are generally sought when the drug is not sufficiently soluble or stable, or when it is difficult to purify, handle or process during manufacturing. Different salts may lead to different solubility, bioavailability and efficacy, and to different organoleptic characteristics or other properties.

The preparation of pharmaceutically suitable salts is a mature technical field. The individual salt-forming acids and bases, their relevant properties and the processes for their preparation are familiar to any person with ordinary training in the formulation of pharmaceuticals. Regardless of whether salt screening studies follow trial-and-error procedures or other methods (such as high-throughput synthesis), it would be hard to demonstrate that an inventive activity is involved.

It has been common in the pharmaceutical industry to file patent applications on particular salts as a means of ‘evergreening’. If such patents are granted, generic drugs may be prevented from entering the market. For instance, Dr. Reddy's Laboratories sought marketing approval for amlodipine maleate in the United States. However, the US Court of Appeals for the Federal Circuit concluded that Pfizer’s basic patent for amlodipine was infringed, as it covered salt forms of the drug, including its maleate salt.

The choice of a salt for a particular drug is important in obtaining certain desirable characteristics related to stability, bioavailability, manufacturability and route of treatment.

---

65 Often, generic references to 'all pharmaceutically acceptable salts' are included in patent applications claiming other subject matter, such as a new active ingredient, enantiomer, prodrug, etc.
66 Pfizer Inc. v. Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc., United States Court of Appeals, Federal Circuit, 359 F.3d 1361, 27 February 2004. The patent on besylate of amlodipine was later invalidated. See Box 2.
67 The patent claimed certain dihydropyridine compounds and their acid addition salts, including the compound having the common name amlodipine, and its salts.
administration to the patient.\textsuperscript{68} However, the fact that a particular salt has advantages over the free base/acid drug or other salts does not mean that it results from an inventive activity. Thus, while a salt may be novel and industrially applicable, it will very rarely comply with the requirement of inventive step. Moreover, as noted in the Indian \textit{Revised Draft Guidelines for Examination of Patent Applications in the Field of Pharmaceuticals},

choosing a better alternative/substitute from the known alternative from the prior art to obtain the known results would not go beyond what may be normally expected from person skilled in the art. Thus, when the solution is from a limited set of alternatives which is obvious to try, even the demonstration of surprising effects etc. do not provide any answer to the obviousness.\textsuperscript{69}

A salt will not meet the inventive step requirement even when a pharmacologically acceptable anion selected from a list of salt-forming candidates has been seldom used for approved drugs. For instance, if the most commonly used anion is hydrochloride, but besylate is chosen because of advantageous properties, this does not mean that the person skilled in the art would have been unable to carry out experiments and choose a substitute to the known alternative from the prior art.\textsuperscript{70} Thus, a patent on the besylate salt of amlodipine was revoked on grounds of lack of inventive step in Canada and the United States (see Box 2).

\textbf{Box 2}

\textbf{Revocation of Patents on a Besylate Salt}

On 11 July 2009, the Canadian Federal Court invalidated patent number 1,321,393 claiming amlodipine besylate (Pfizer's 'NORVASC'), as being obvious. The patent claimed that the besylate salt showed a "unique combination of good solubility, good stability, non-hygrosopicity and good processability which makes it outstandingly suitable for the preparation of pharmaceutical formulations of amlodipine."

The Court found that salt screening, a "well-known" process, was used to find the patented salt. It noted that "[a]ll of this is routine for a person skilled in the art at the time" and that a skilled person "would be motivated to test sulphonic acid salts in general and would have every reason to test the besylate salt as this had already been shown to offer advantages over other salts in terms of stability."

A patent on the same salt was invalidated in the United States by the US Court of Appeals for the Federal Circuit.\textsuperscript{71} The Court found that "a reasonable fact-finder could only conclude that Apotex has shown by clear and convincing evidence that the skilled artisan would indeed have been so motivated to combine the prior art to produce the besylate salt of amlodipine" and concluded that "[t]he record also satisfies us that . . . a reasonable fact-finder could only conclude that the skilled artisan would have had a reasonable expectation of success with the besylate salt form of amlodipine."

\textsuperscript{69} Para. 8.6.
\textsuperscript{70} See \textit{Revised Draft Guidelines for Examination of Patent Applications in the Field of Pharmaceuticals}, 2014, para. 8.1, example 3.
\textsuperscript{71} \textit{Pfizer, Inc. v. Apotex, Inc.}, 2006-1261;22 March 2007 (emphasis added).
The Court also stated that "the prior art provided not only the means of creating acid addition salts but also predicted the results, which Pfizer merely had to verify through routine testing," and that Pfizer's experimentation with amlodipine besylate was "not equivalent to the trial and error procedures often employed to discover a new compound where the prior art gave no motivation or suggestion to make the new compound nor a reasonable expectation of success." It added that "the acid addition salt formulation has no effect on the therapeutic effectiveness of the active ingredient and the prior art heavily suggests the particular anion used to form the salt."

There is abundant case law illustrating courts’ analyses of patents covering salts. For instance, on 27 July 2013, India’s Intellectual Property Appellate Board revoked patent IN 221171 of 20 June 2008 covering the salt/crystalline form of ditosylate, a cancer drug. 72 The revocation was based on lack of inventive step (and inconsistency with section 3(d) of the Patent Act). The patent would have expired more than two years after the compound patent in 2022. Another case is presented in Box 3.

**Box 3**

**Revocation of Tenofovir Patent in China** 73

The Patent Review Board of China’s State Intellectual Property Office rejected Gilead Sciences’ claims regarding their Viread patent covering the compounds of the fumarate of Bis (POC) PMPA, which is an active ingredient in treating HIV, AIDS and Hepatitis B, known under the trade name ‘Viread’.

The Board declared all claims invalid. Claim 1 was found to lack inventive step over the combined teachings of two prior art documents. Part of claim 1 was directed at the fumarate of Bis (POC) PMPA, which according to the description, has unexpected physical and chemical properties when compared to its free base. Some of the Bis (POC) PMPA properties were disclosed in one piece of prior art. Another disclosed a number of acids, including fumaric acid, for forming salts of a compound similar to the Bis (POC) PMPA. The Board concluded that those skilled in the art would be motivated to improve the stability of the free base by trying different salts based on the common understanding that salts of the free base usually retain their pharmacological activity.

The Board also concluded that experimental data comparing only the chemical stability of citrate and fumarate are not sufficient to show that fumarate is considerably better than all other salts.

**Source:** Lexology, www.lexology.com/library/detail.aspx?g=8fa9fa74-8bce-4f11-b77a-43a677bf66fb.

---

72 See www.pharmamedtechbi.com/~media/Supporting%20Documents/Pharma%20News/2013/August/GSK%20Fresenius%20IPAB%20Order%20Aug%201%202013.pdf.

73 Patent applications on tenofovir Disoproxil fumarate were rejected in other countries, such as India and Brazil, where pre-grant oppositions were filed (see e.g., http://spicyip.com/2009/09/patent-office-rejected-tenofovir.html).
6. **Ethers and Esters**

Ethers, such as e-series glycol ethers, and esters\(^ {74} \) are sometimes used in pharmaceutical products. The use of esters may improve the safety or efficacy of a drug. Esters and ethers are generally more lipid soluble than salts, thereby altering tissue penetrability and sometimes the rate of release, as with steroids. However, they would not generally enhance the therapeutic efficacy of a drug.

Generic formulas for ethers and esters are of the type \( R_1-O-R_2 \) and \( R_1-C-O- R_2 \), respectively, where \( R_1 \) and \( R_2 \) are independent alkyl groups.

The preparation of ethers and esters of a compound is part of the common knowledge of a person skilled in pharmaceuticals. It is generally obvious to predict the claimed advantages that an ether or ester will provide compared to the free base or free acid compound. A skilled person would be able to anticipate the characteristics that may be achieved and how the compound will perform.

The considerations applicable to salts are generally also applicable to ethers and esters.

7. **Compositions**

A large number of patent applications claim ‘compositions’ (or ‘formulations’) of known drugs.

The formulation of active ingredients using pharmaceutically acceptable carriers or excipients – such as fillers or diluents, binders, stabilizing agents (such as pH regulators), disintegrants, and lubricants – is a mature technological field, and falls within the competence of a person normally skilled in pharmaceutical formulation. The techniques for the preparation of compositions to ensure the delayed (e.g., using one or more enteric coating layers) or rapid release of an active ingredient are also well known. It is obvious for a person working in formulation to seek the most appropriate form for administering a drug. Similarly, the micronization of a drug (for instance, when it is poorly soluble) is a well-known method to improve drug delivery that only entails, in addition, changes in the physical form.\(^ {75} \)

If granted, patents over formulations may obstruct the functioning of the generic market for the respective active ingredient, even if off-patent, particularly when a given composition is the most suitable for administration of a medicine. The blocking effect of a composition patent was demonstrated by the Canadian Federal Court’s decision in *AstraZeneca Canada Inc. et al. v. Apotex Inc.*, 2015 FC 322, issued on 16 March 2015.\(^ {76} \) At issue was Canadian patent number 1,292,693, a formulation patent of omeprazole (first

---

\(^ {74} \) Ethers are two simple hydrocarbon chains that are separated by an oxygen. Esters are similar except they have a double-bonded oxygen on the carbon adjacent to the oxygen separating the two hydrocarbon groups. See [www.sussexvt.k12.de.us/science/Chemical%20Substances/Ethers%20and%20Esters.htm](http://www.sussexvt.k12.de.us/science/Chemical%20Substances/Ethers%20and%20Esters.htm).

\(^ {75} \) See, e.g. *Revised Draft Guidelines for Examination of Patent Applications in the Field of Pharmaceuticals*, para. 8.10, example 6.

patented in 1978) covering “[A]n oral pharmaceutical preparation composition comprising. . . an inert subcoating which is soluble or rapidly disintegrating in water disposed on said core region, said subcoating comprising one or more layers of material selected from among tablet excipients and polymeric film forming compounds.” As a result of the Court’s decision, the generic firm Apotex was prevented from commercializing the product.

While a particular composition may have some advantageous effects (e.g., increased bioavailability, more stability during storage, inhibiting gastric acid secretion), this does not mean that its preparation results from an inventive activity. As noted, formulation techniques and the substances that may be used for that purpose are part of the common knowledge of a person skilled in the art. Hence, compositions would normally fail to satisfy the inventive step requirement if, the common knowledge of a person trained in pharmaceutical formulation is taken into account, even in the absence of documents directly referring to the particular drug.

Sometimes claims refer to pharmacokinetic parameters (such as $T_{\text{max}}$, $C_{\text{max}}$, under the plasma drug concentration-time curve – AUC). This type of claim is objectionable to the extent that it describes the alleged biological effects of the composition in the body; that is, what the claimed invention does and not what it actually is. This type of claim may in fact mask a method of treatment claim under the appearance of a product claim.

8. **Doses**

Some patent applications claim independently, or as part of a broader claim, the dose for administering a particular drug. Patents over doses constitute another form of ‘evergreening’, potentially blocking the marketing of generic versions when, for instance, the prescribed dose of a drug is included in the range covered by the patent. Thus, a report by the US Government Accountability Office noted:

> the practice commonly known as producing line extensions—deriving new products from existing compounds by making small changes to existing products, such as changing a drug’s dosage…. . According to analysts, these changes are typically made to blockbuster drugs shortly before their patents expire. Some analysts also concluded that this practice redirects resources that otherwise could be applied to developing new and innovative drugs.  

Often, claims of this type are drafted with the appearance of a claim covering a composition. For instance, ‘a formulation that achieves a therapeutic effect with a daily dose ranging from about 0.1 to about 200 mg of compound YY’.

Dose-based claims are subject to objections of lack of industrial applicability. While they may be drafted in a manner that suggests a product claim, in reality they cover a **method of medical treatment** that, by definition, produces effects in the body and is deprived of industrial applicability. The examiner is bound to establish the true nature and scope of a claim, independent of how it has been drafted.


In addition to the lack of industrial applicability, in countries where methods of treatment are excluded from patentability, a dose-based claimed would be unacceptable.

In countries where considerations around industrial applicability would not arise, claims relating to doses must be examined under the novelty and inventive step criteria. In Australia, for instance, Astra Zeneca asserted against generic producers patent AU200023051 relating to the use of a ‘low dose’ (namely, doses of 5 or 10mg) of rosuvastatin to treat hypercholesterolemia. The patent was declared invalid on grounds of novelty and inventive step, among other reasons.  

9. Combinations

Often two (or more) known drugs are combined in a single product, and patent protection over the combination is claimed.

Many patent laws specifically exclude from patentability the juxtaposition or combination of known products, unless a new or synergistic effect may be found, such as when one of the drugs enhance or magnify the therapeutic effects of the other. A typical example is the combination of certain doses of codeine with acetaminophen or ibuprofen to enhance pain relief. In the absence of such synergistic effect, a patent application on a combination of drugs will be rejected by many patent offices, or a patent will be revoked by courts. For instance, in *Novo Nordisk A/S v. Caraco Pharmaceutical Laboratories Ltd.*, the US Court of Appeals confirmed in 2013 a district court decision that held invalid patent number 6,677,358 with regard to a combination of repaglinide with metformin. The District Court had found that:

it was obvious to try combination therapy using metformin and repaglinide to treat Type II diabetes. . . It was apparently well-known in the art that two drugs having different mechanisms for attacking diabetes may be more effective than one, and so drugs were often tested in combination therapy after demonstrating effectiveness in monotherapy. . . Combination therapy using insulin sensitizers and insulin secretagogues was common at the time, and metformin was the most widely-used insulin sensitizer as of the ‘358 patent’s filing date.

As noted by the Indian *Revised Draft Guidelines for Examination of Patent Applications in the Field of Pharmaceuticals*:

Quite often, the claims of combination of pharmaceutical products escape the question of novelty and are dealt under the inventive step. . [but] sometimes it may happen that the combination has already fallen in the public domain and hence, should be dealt under novelty also.  

A novelty objection may be articulated, for instance, when the medical profession already used drugs in combination to attain a certain therapeutic result before a patent

---


80 *Revised Draft Guidelines for Examination of Patent Applications in the Field of Pharmaceuticals*, para. 7.7.
application was filed. In fact, most claimed combinations have already been tested in medical practice by administering the components independently.  

A claim over a combination of drugs may also be disallowed on the grounds that in practical terms, they are equivalent to claims on a medical treatment, whose patentability is excluded by lack of industrial applicability, or in some cases, by a specific exclusion.

10. Prodrugs

Many medicines are commercialized as prodrugs. A prodrug is a precursor of a drug, which undergoes a chemical conversion by metabolic processes in the body before becoming therapeutically active. Some prodrugs are activated inside the cells (Type I) while others become active extracellularly (Type II). One example is tenofovir disoproxil fumarate, a prodrug of tenofovir, an antiretroviral of the class known as nucleotide analogue reverse transcriptase inhibitors (nRTIs). Another example is sulfasalazine, a prodrug that is broken down by bacteria into 5-aminosalicylic acid (5ASA) and sulfapyridine to become therapeutically active.

Prodrugs are often claimed independently from the active drug when a patent on the active drug has expired or is about to. In some cases, patent applications contain generic references to ‘all prodrugs’ of a given compound. The active moiety of the drug and prodrug is the same; hence the latter will generally lack inventive step. A prodrug may be regarded as the original drug ‘in disguise’ as noted by a British court in the case of hetacillin, an acetone adduct of ampicillin that is immediately hydrolyzed in the body to ampicillin.

In examining patent claims relating to prodrugs, consideration should be given to the extent to which the prodrug is inactive (or much less active than the corresponding original active drug) and, once metabolized, provides the required level of the active drug. A prodrug may have advantages compared to the basic drug (e.g., better stability and bioavailability, fewer side effects, better pharmacokinetic profile, increased concentration of the drug at the site of action, and duration of action of drug). However, a prodrug may also present disadvantages, such as poor aqueous stability and incomplete or slow in vivo conversion. A key consideration under patent law is whether the development of a new prodrug is the outcome of an inventive activity or of routine research and experimentation.


82 Ibid.


84 A typical example is enalapril, an ethyl ester prodrug of enalaprilat, which greatly enhances the absorption in the gastrointestinal tract of the active ingredient.
11. **Metabolites**

An active metabolite is the compound that remains after a drug is metabolized by the body. Enzymes in the liver are responsible for chemically changing drug components into metabolites, which contain the same functional group as its parent drug. An active metabolite retains most, if not all, of the properties of its parent drug, until its carbon structure blends into larger structures or is reduced to smaller structures.  

Active metabolites may be identified, synthesized, and commercialized as a product different from the parent drug. Often, patent applications on specific active metabolites are filed. In some cases, however, generic references to ‘all metabolites’ are included in patents claiming an active ingredient.

Active metabolites cannot be deemed an ‘invention’ because they are naturally produced through the metabolism. Although there may be advantages in administering an active metabolite, as compared to the parent drug, any advantages do not stem from an inventive activity. Isolating and characterizing a metabolite can be done using knowledge common to a person skilled in the pharmaceutical field. Moreover, an active metabolite may be deemed as deprived of novelty, based on the concept of inherency.

For instance, in *Schering Corp. v. Geneva Pharmaceuticals, Inc.*, 339 F.3d 1373 (Fed. Cir. 2003), the US Court of Appeals for the Federal Circuit examined the validity of a patent over desacboethoxyloratadine (DCL), the active metabolite of loratadine, a compound used to suppress allergic reactions. The Court found the patent invalid because the alleged invention was anticipated by the patent on loratadine, meaning its novelty was lost. The Court stated that when a feature is inherently implied in the piece of prior art, the claimed invention is anticipated. In the United Kingdom, claims on metabolites may also face objections of lack of novelty even if a prior patent does not disclose how to manufacture the pure metabolite. In *Merrell Dow Pharmaceuticals Inc. v. HN Norton & Co. Ltd* [1996] R.P.C. 76 (HL), the House of Lords found that to the extent that the prior patent described that administering terfenadine will produce chemical reactions in the patient’s body and that antihistamine effects will be achieved, this was sufficient to allow any person to produce the claimed compound through metabolism.

12. **New Medical Use**

Claims over a new medical use of a known medicine (often called ‘second use claims’) account for a good part of the proliferation of pharmaceutical patents. When a patent is about to expire or has expired, pharmaceutical companies may attempt to extend their monopoly by applying for patents for one or more new therapeutic uses of an active ingredient. If granted, such patents may be used to prevent generic competition, and to charge high prices for drugs that are actually off-patent. For instance, AZT (Zidovudine), a drug effective in both the treatment of AIDS and the reduction of mother-to-child transmission, was first developed as a cancer treatment in 1964 in the United States, by the National Cancer Institute in Detroit. Eleven years later, its antiretroviral activity was recognized in studies also conducted at the National Cancer Institute. Burroughs Wellcome laboratories carried out subsequent clinical

---

85 See, e.g., Edward D. Harris, Biochemical Facts behind the Definition and Properties of Metabolites, available at [www.fda.gov/ohrms/dockets/ac/03/briefing/3942b1_08_Harris%20Paper.pdf](http://www.fda.gov/ohrms/dockets/ac/03/briefing/3942b1_08_Harris%20Paper.pdf).
trials and first patented the antiretroviral use of AZT in 1985, which became the first breakthrough in AIDS therapy. Prices for AZT were significantly higher in countries where patent protection was obtained than in those where generic competition was possible.

‘Second use’ claims have been accepted in some jurisdictions. In Europe, for instance, on the basis of a fiction of novelty and industrial applicability, they were allowed if drafted as ‘Use of a substance or composition X for the manufacture of a medicament for therapeutic application Z’. This so-called ‘Swiss-type’ claim gives the appearance of a claim to an invention with a technical character, which is actually absent.

While some countries followed the EPO approach, others explicitly exclude the patentability of new uses of known medicines. In India, for instance, the Intellectual Property Appellate Board rejected an application that claimed the use of known fumaric acid derivatives for a second medical indication. The examiner stated that the claims were not allowable under section 2(1)(j) of the Indian Patent Act in that they related neither to product nor process, and the compounds of the invention were admittedly known. To overcome the objections, the claims were amended to product claims, but the issue of lack of novelty remained. The Controller refused the application on the grounds of lack of novelty, a decision later upheld by the Intellectual Property Appellate Board.

Knowing that an existing compound can also be used to treat other diseases or symptoms is not an invention, as the pharmacological effect is intrinsic to the compound. The new use is simply discovered through clinical trials or observation during the marketing period. Patentability of a use claim can be denied based on the grounds that it is a discovery rather than an invention.

A claim on the new use of a medicine is equivalent to a claim on a method of medical treatment. The only contribution made in such a claim is information for the physician about the way to use a drug to achieve a new therapeutic effect. The effects take place in the body. There is no technical effect, since the claim does not cover the product and process of manufacture, but merely a given form of use. It does not matter how a claim relating to a new use of a drug is drafted; it does not change its essence as a claim on method of treatment.

The denial of patentability of new use claims is fully compatible with the TRIPS Agreement, which only requires the grant of patents with regard to products and processes, and does not define ‘invention’. Furthermore, the TRIPS Agreement specifically allows WTO members to exclude from patentability, inter alia, methods of medical treatment (article 27.3(a)).


The ‘Swiss claim’ format became unnecessary after an amendment to the European Patent Convention entered into force in 2007. The EPO held that “[W]here the subject matter of a claim is rendered novel only by a new therapeutic use of a medicament, such claim may no longer have the format of a so-called Swiss-type claim as instituted by decision G 5/83” (Decision G 0002/08 (Dosage regime/ABBOTT RESPIRATORY) of 19.2.2010, available at https://www.epo.org/law-practice/case-law-appeals/recent/g080002ex1.html).

See, e.g., article 21 of Decision 486, Common Regime on Industrial Property, Andean Community of Nations; section 3(d) of the Indian Patent Act (as amended in 2005).

As noted above, in some cases claims on new use have the appearance of a composition or combination claim.
In some cases, the potential new medical uses of a known drug are claimed in patent applications but not sufficiently supported by medical evidence. For instance, the Canadian Federal Court revoked a patent in which Eli Lilly claimed that it had discovered that olanzapine had a “marked superiority in the treatment of schizophrenia” compared with other compounds of the larger group it had previously patented. The Court found that Eli Lilly had claimed the second monopoly on the basis of studies that failed to establish any particular treatment advantage of olanzapine over the already-patented class to which it belonged. Moreover, it was found that Eli Lilly had filed:

at least 29 other Canadian patent applications relating to olanzapine, purporting to have invented at least 16 distinct new and surprising uses for the compound, ranging from sexual dysfunction to autism. The majority of these other patent applications contained no reference to actual research conducted, or contained an ambiguous reference to clinical studies that may or may not have been conducted before the filing of the corresponding patent applications.

IV. CONCLUSIONS

Patent offices and courts can apply criteria for the assessment of patent claims that are both consistent with the conception of the patent regime as a system for the reward of genuine technical contributions and with the standards set out by the TRIPS Agreement. Importantly, there is no limitation in the TRIPS Agreement or in other international instruments preventing States from defining and applying specific criteria for assessing patentability that take into account the particular characteristics of a certain field of technology, such as pharmaceuticals.

The application of technically sound, rigorous criteria may avoid the misuse of patents as a tool to block the market entry of generic products, and the ensuing adverse effects on pricing and affordability of medicines. As noted above, there are many precedents in both developed and developing countries supporting the application of criteria to different types of claims that would allow for the grant of patents in this field when it is justified by the technical contribution made, with the exclusion of developments that are not actually new or are just the outcome of routine activities.

---

92 Ibid.
93 Ibid., para. 67.
<table>
<thead>
<tr>
<th>No.</th>
<th>Date</th>
<th>Title</th>
<th>Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>November 2005</td>
<td>Overview of the Sanitary and Phytosanitary Measures in QUAD Countries on Tropical Fruits and Vegetables Imported from Developing Countries</td>
<td>Ellen Pay</td>
</tr>
<tr>
<td>2</td>
<td>November 2005</td>
<td>Remunerating Commodity Producers in Developing Countries: Regulating Concentration in Commodity Markets</td>
<td>Samuel G. Asfaha</td>
</tr>
<tr>
<td>3</td>
<td>November 2005</td>
<td>Supply-Side Measures for Raising Low Farm-gate Prices of Tropical Beverage Commodities</td>
<td>Peter Robbins</td>
</tr>
<tr>
<td>4</td>
<td>November 2005</td>
<td>The Potential Impacts of Nano-Scale Technologies on Commodity Markets: The Implications for Commodity Dependent Developing Countries</td>
<td>ETC Group</td>
</tr>
<tr>
<td>5</td>
<td>March 2006</td>
<td>Rethinking Policy Options for Export Earnings</td>
<td>Jayant Parimal</td>
</tr>
<tr>
<td>6</td>
<td>April 2006</td>
<td>Considering Gender and the WTO Services Negotiations</td>
<td>Meg Jones</td>
</tr>
<tr>
<td>7</td>
<td>July 2006</td>
<td>Reinventing UNCTAD</td>
<td>Boutros Boutros-Ghali</td>
</tr>
<tr>
<td>8</td>
<td>August 2006</td>
<td>IP Rights Under Investment Agreements: The TRIPS-plus Implications for Enforcement and Protection of Public Interest</td>
<td>Ermias Tekeste Biadgleng</td>
</tr>
<tr>
<td>9</td>
<td>January 2007</td>
<td>A Development Analysis of the Proposed WIPO Treaty on the Protection of Broadcasting and Cablecasting Organizations</td>
<td>Viviana Munoz Tellez and Andrew Chege Waitara</td>
</tr>
<tr>
<td>10</td>
<td>November 2006</td>
<td>Market Power, Price Formation and Primary Commodities</td>
<td>Thomas Lines</td>
</tr>
<tr>
<td>11</td>
<td>March 2007</td>
<td>Development at Crossroads: The Economic Partnership Agreement Negotiations with Eastern and Southern African Countries on Trade in Services</td>
<td>Clare Akamanzi</td>
</tr>
<tr>
<td>12</td>
<td>June 2007</td>
<td>Changes in the Governance of Global Value Chains of Fresh Fruits and Vegetables: Opportunities and Challenges for Producers in Sub-Saharan Africa</td>
<td>Temu A.E and N.W Marwa</td>
</tr>
<tr>
<td>13</td>
<td>August 2007</td>
<td>Towards a Digital Agenda for Developing Countries</td>
<td>Dalindyebo Shabalala</td>
</tr>
<tr>
<td>14</td>
<td>December 2007</td>
<td>Analysis of the Role of South-South Cooperation to Promote Governance on Intellectual Property Rights and Development</td>
<td>Ermias Tekeste Biadgleng</td>
</tr>
<tr>
<td>16</td>
<td>January 2008</td>
<td>Liberalization of Trade in Health Services: Balancing Mode 4 Interests with</td>
<td>Joy Kategekwa</td>
</tr>
<tr>
<td>Issue</td>
<td>Date</td>
<td>Title</td>
<td>Authors</td>
</tr>
<tr>
<td>------------</td>
<td>------------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------------------------------</td>
</tr>
<tr>
<td>17 July 2008</td>
<td></td>
<td>Obligations to Provide Universal Access to Basic Services</td>
<td>Vicente Paolo B. Yu III</td>
</tr>
<tr>
<td>18 December 2008</td>
<td></td>
<td>Unity in Diversity: Governance Adaptation in Multilateral Trade Institutions Through South-South Coalition-Building</td>
<td>Xuan Li</td>
</tr>
<tr>
<td>19 December 2008</td>
<td></td>
<td>Patent Counts as Indicators of the Geography of Innovation Activities: Problems and Perspectives</td>
<td>Xuan Li</td>
</tr>
<tr>
<td>21 June 2009</td>
<td></td>
<td>IPR Misuse: The Core Issue in Standards and Patents</td>
<td>Xuan Li and Baisheng An</td>
</tr>
<tr>
<td>22 July 2009</td>
<td></td>
<td>Policy Space for Domestic Public Interest Measures Under TRIPS</td>
<td>Henning Grosse Ruse – Khan</td>
</tr>
<tr>
<td>23 June 2009</td>
<td></td>
<td>Developing Biotechnology Innovations Through Traditional Knowledge</td>
<td>Sufian Jusoh</td>
</tr>
<tr>
<td>24 May 2009</td>
<td></td>
<td>Policy Response to the Global Financial Crisis: Key Issues for Developing Countries</td>
<td>Yılmaz Akyüz</td>
</tr>
<tr>
<td>25 October 2009</td>
<td></td>
<td>The Gap Between Commitments and Implementation: Assessing the Compliance by Annex I Parties with their Commitments Under the UNFCCC and its Kyoto Protocol</td>
<td>Vicente Paolo Yu III</td>
</tr>
<tr>
<td>27 April 2010</td>
<td></td>
<td>Export Dependence and Sustainability of Growth in China and the East Asian Production Network</td>
<td>Yılmaz Akyüz</td>
</tr>
<tr>
<td>28 May 2010</td>
<td></td>
<td>The Impact of the Global Economic Crisis on Industrial Development of Least Developed Countries</td>
<td>Report Prepared by the South Centre</td>
</tr>
<tr>
<td>29 May 2010</td>
<td></td>
<td>The Climate and Trade Relation: Some Issues</td>
<td>Martin Khor</td>
</tr>
<tr>
<td>30 May 2010</td>
<td></td>
<td>Analysis of the Doha Negotiations and the Functioning of the World Trade Organization</td>
<td>Martin Khor</td>
</tr>
<tr>
<td>31 July 2010</td>
<td></td>
<td>Legal Analysis of Services and Investment in the CARIFORUM-EC EPA: Lessons for Other Developing Countries</td>
<td>Jane Kelsey</td>
</tr>
<tr>
<td>32 November 2010</td>
<td></td>
<td>Why the IMF and the International Monetary System Need More than Cosmetic Reform</td>
<td>Yılmaz Akyüz</td>
</tr>
<tr>
<td>33 November 2010</td>
<td></td>
<td>The Equitable Sharing of Atmospheric and Development Space: Some Critical Aspects</td>
<td>Martin Khor</td>
</tr>
<tr>
<td>34 November 2010</td>
<td></td>
<td>Addressing Climate Change through Sustainable Development and the Promotion of Human Rights</td>
<td>Margreet Wewerinke and Vicente Paolo Yu III</td>
</tr>
<tr>
<td>35 January 2011</td>
<td></td>
<td>The Right to Health and Medicines: The</td>
<td>Germán Velásquez</td>
</tr>
<tr>
<td>Issue Date</td>
<td>Title</td>
<td>Authors</td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>March 2011</td>
<td>The Nagoya Protocol on Access and Benefit Sharing of Genetic Resources: Analysis and Implementation Options for Developing Countries</td>
<td>Gurdial Singh Nijar</td>
<td></td>
</tr>
<tr>
<td>March 2011</td>
<td>Capital Flows to Developing Countries in a Historical Perspective: Will the Current Boom End with a Bust?</td>
<td>Yılmaz Akyüz</td>
<td></td>
</tr>
<tr>
<td>May 2011</td>
<td>The MDGs Beyond 2015</td>
<td>Deepak Nayyar</td>
<td></td>
</tr>
<tr>
<td>May 2011</td>
<td>Operationalizing the UNFCCC Finance Mechanism</td>
<td>Matthew Stilwell</td>
<td></td>
</tr>
<tr>
<td>July 2011</td>
<td>Risks and Uses of the Green Economy Concept in the Context of Sustainable Development, Poverty and Equity</td>
<td>Martin Khor</td>
<td></td>
</tr>
<tr>
<td>September 2011</td>
<td>Pharmaceutical Innovation, Incremental Patenting and Compulsory Licensing</td>
<td>Carlos M. Correa</td>
<td></td>
</tr>
<tr>
<td>December 2011</td>
<td>Rethinking Global Health: A Binding Convention for R&amp;D for Pharmaceutical Products</td>
<td>Germán Velásquez and Xavier Seuba</td>
<td></td>
</tr>
<tr>
<td>March 2012</td>
<td>Mechanisms for International Cooperation in Research and Development: Lessons for the Context of Climate Change</td>
<td>Carlos M. Correa</td>
<td></td>
</tr>
<tr>
<td>March 2012</td>
<td>The Staggering Rise of the South?</td>
<td>Yılmaz Akyüz</td>
<td></td>
</tr>
<tr>
<td>April 2012</td>
<td>Climate Change, Technology and Intellectual Property Rights: Context and Recent Negotiations</td>
<td>Martin Khor</td>
<td></td>
</tr>
<tr>
<td>June 2013</td>
<td>Waving or Drowning: Developing Countries After the Financial Crisis</td>
<td>Yılmaz Akyüz</td>
<td></td>
</tr>
<tr>
<td>February 2014</td>
<td>Crisis Mismanagement in the United States and Europe: Impact on Developing Countries and Longer-term Consequences</td>
<td>Yılmaz Akyüz</td>
<td></td>
</tr>
<tr>
<td>July 2014</td>
<td>Obstacles to Development in the Global Economic System</td>
<td>Manuel F. Montes</td>
<td></td>
</tr>
<tr>
<td>August 2014</td>
<td>Tackling the Proliferation of Patents: How to Avoid Undue Limitations to Competition and the Public Domain</td>
<td>Carlos M. Correa</td>
<td></td>
</tr>
<tr>
<td>September 2014</td>
<td>Regional Pooled Procurement of Medicines in the East African Community</td>
<td>Nirmalya Syam</td>
<td></td>
</tr>
<tr>
<td>September 2014</td>
<td>Innovative Financing Mechanisms: Potential Sources of Financing the WHO</td>
<td>Deborah Ko Sy, Nirmalya Syam and Germán</td>
<td></td>
</tr>
</tbody>
</table>
October 2014  
Tobacco Convention  
Velásquez

November 2014  
Patent Protection for Plants: Legal Options for Developing Countries  
Carlos M. Correa

Sangeeta Shashikant

November 2014  
Globalization, Export-Led Growth and Inequality: The East Asian Story  
Mah-Hui Lim

November 2014  
Patent Examination and Legal Fictions: How Rights Are Created on Feet of Clay  
Carlos M. Correa

December 2014  
Transition Period for TRIPS Implementation for LDCs: Implications for Local Production of Medicines in the East African Community  
Nirmalya Syam

January 2015  
Internationalization of Finance and Changing Vulnerabilities in Emerging and Developing Economies  
Yılmaz Akyüz

March 2015  
Guidelines on Patentability and Access to Medicines  
Germán Velásquez

September 2015  
Intellectual Property in the Trans-Pacific Partnership: Increasing the Barriers for the Access to Affordable Medicines  
Carlos M. Correa

October 2015  
Foreign Direct Investment, Investment Agreements and Economic Development: Myths and Realities  
Yılmaz Akyüz